Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers - European Medical Journal

Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

Download PDF
Hilary Calvert2
Nicoletta Colombo,3 Eric Pujade-Lauraine,4 Andrew Tutt,5 Eric Van Cutsem6

Tristin Abair has no relevant financial relationships to disclose. Hilary Calvert has received consulting fees from AstraZeneca and holds intellectual property rights/is a patent holder for rucaparib (a Clovis Oncology product). Nicoletta Colombo has received consulting fees from AstraZeneca. Eric Pujade-Lauraine has received consulting fees from AstraZeneca, Pfizer, and Roche. Andrew Tutt has received grants/research support from AstraZeneca, Myriad Genetics, and Roche; received honoraria or consulting fees from EISAI, Merck Serono, and Vertex; received royalties from ICR Rewards to Inventors Scheme regarding olaparib in BRCA1/2 malignancy; and has been named on a patent (KCL) for genome instability. Eric Van Cutsem has performed contracted research for Amgen, Bayer, Boehringer Ingelheim, Celgene, Lilly, Merck Serono, Novartis, Roche, and Sanofi.


Editorial assistance was provided by Ms Trudy Grenon Stoddert, prIME Oncology.


AstraZeneca has provided a sponsorship grant toward this independent programme. In addition, this manuscript is supported by a grant from Clovis Oncology.

EMJ Oncol. ;3[2]:49-58. DOI/10.33590/emjoncol/10313170.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biological basis for targeting this process in oncology, delivered by Prof Calvert. This was followed by a discussion from Prof Pujade-Lauraine that focussed on patient selection for PARP inhibition and the role for these agents in BRCA -mutated and BRCA -like cancers. Next, Prof Colombo presented a clinical scenario of BRCA -associated ovarian cancer and examined optimal treatment options in the first-line setting and for progressive disease. She also highlighted current clinical data and ongoing trials evaluating PARP inhibition in advanced ovarian cancer. Prof Tutt then discussed the potential role for PARP inhibitors in patients with breast cancer, focussing on a clinical scenario of triple-negative disease and emphasising current and investigational treatment options. Lastly, Prof Van Cutsem described emerging data and ongoing clinical studies evaluating PARP inhibition in the treatment of patients with pancreatic and gastric cancers, and how this could impact future clinical practice. The programme also included a PARP quiz, in which participants were polled at the beginning and conclusion of the symposium to examine their knowledge and practice patterns regarding the use of PARP inhibitors in oncology. The key highlights from these presentations and the PARP quiz are summarised herein.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now